Gyrolab® xPand immunoassay system
Gyrolab xPand is a high-throughput, compact disk (CD) based microfluidic immunoassay platform for unattended parallel processing of up to 5 CDs, generating 560 data points in 5 hours.
Receive your quote directly from the manufacturer.
Limited mouse serum/plasma volume (<10 µL) restricts the number of PK/ADA assays that can be performed using traditional
Mouse pharmacokinetics study bioanalysis of NBE drug
Mouse pharmacokinetics/immunogenicity (PK/ADA) data packages are essential milestones for advancing a New Biologic Entity (NBE) from research into development. A major bottleneck in mouse PK/ADA bioanalysis is the limited serum or plasma sample volume available—typically less than 10 µL for a full time course of ~10 timepoints. Traditional platforms such as ELISA and MSD generally require this entire volume for only one or two assays, which becomes increasingly restrictive as drug formats grow more complex (e.g., bispecifics, trispecifics) and require multiple analytical readouts. The Gyrolab Xpand system addresses this limitation by enabling several assays to be performed from a single 10 µL sample, generating richer datasets to support project decision making. Its fully automated workflow also improves operational efficiency by reducing hands on time compared with ELISA and MSD, which require manual wash and incubation steps. The primary drawback of the Gyrolab platform is its higher cost, including equipment, consumables, and annual maintenance, relative to conventional bioanalytical methods.
Review Date: 13 Feb 2026 | Gyros Protein Technologies
Great replacement for ELISA.
Antibody binding to analyte
The Gyrolabs instrument basically runs the whole ELISA for you. All you need to do is prepare the samples and antibodies just like you do for normal ELISA. The instrument takes care of adding each component and washing in between steps. You walk away after loading samples and CD. After about 1 hour, the data is ready for analysis.
Review Date: 29 Oct 2020 | Gyros Protein Technologies
High-throughput with good quality and reproducibility.
Analysing drug concentration in plasma or serum
High quality and reproducibility.
Review Date: 22 Oct 2020 | Gyros Protein Technologies
Key Features:
- Run up to five CDs unattended to generate up to 560 immunoassay data points within five hours
- On-deck cooling of samples and reagents
- Mix and match methods/CDs in a single run
- Flexible run setup and analysis
- Software 21 CFR part 11 compliant
- Backed by industry-leading technical support
- Nanoliter-scale, rapid analysis, and wide dynamic range
High-throughput, automated analysis of viral vector titer and process related impurities
Download this application note to see a study that explores a solution to these challenges, by investigating the utility and performance of analyzing viral vector titer and impurities in a continuous 5-CD run (“Gyroplex® panel”) using the Gyrolab® xPand platform and a combination of Gyrolab kits and assay protocols. Two AAV serotypes (AAV2 and AAV9) plus 3 impurities (host-cell proteins [HCPs], endonuclease, and transferrin) were analyzed for each serotype on one instrument.
Your guide to miniaturized immunoassays for biotherapeutics
Building on advances in microfluidics, next-generation immunoassays offer unparalleled capability in automation and miniaturization, generating robust and reproducible results for faster decision-making.
In this eBook, discover the advantages of automated, miniaturized immunoassays across the drug development pathway, from pre-clinical to bioprocessing. Learn about challenges and trends in immunoassay technology and how automated, miniaturized immunoassays can help you maximize productivity across a range of biopharmaceutical applications, including:
- Research and clinical development
- Insulin quantification
- Anti-drug antibody studies
- In-solution affinity determination
- Vaccine development and production
In-solution affinity determination using Gyrolab systems
In this technical note, Gyros Protein Technologies demonstrates how using Gyrolab systems can simplify the accurate and rapid analysis of high affinity ligands to determine affinity and activity.
TechTalk: Scaling bioanalysis through automation with expert CRO insights
Friday, March 27 at 16:00 GMT | 17:00 CET | 12:00 EDT | 09:00 PDT
As bioanalysis demands continue to rise, driven by expanding study portfolios, accelerated timelines, and fluctuating project volumes, CROs and pharmaceutical organizations are under increasing pressure to scale efficiently while maintaining regulatory‑ready data quality. Automation is becoming essential for meeting these expectations, enabling teams to increase throughput without adding operational complexity or additional headcount.
This SelectScience® TechTalk brings together valuable CRO insight from an expert working at the forefront of modern bioanalysis: Jason McGraw, Application Scientist, Charles River Laboratories. He will discuss how automated Gyrolab® immunoassay workflows are being implemented to boost productivity, reduce hands‑on time, and deliver consistent pharmacokinetics (PK) data across diverse study types.
In just 20 minutes, attendees will gain practical guidance on how automation is reshaping bioanalytical operations, supporting flexible scaling and helping teams meet rising regulatory expectations in today’s demanding scientific environment.
Key learning objectives:
- Gain insight into real-world implementation of Gyrolab immunoassay systems in a CRO environment.
- Understand how automated Gyrolab workflows support high-throughput bioanalysis without increasing operational complexity.
- Learn how CROs manage variable study volumes and aggressive timelines using standardized, automated assays.
- Explore strategies to reduce hands-on time and analyst variability while maintaining data quality and reproducibility.
- Identify opportunities to improve resource efficiency and turnaround times in PK bioanalysis.
Who should attend?
- Bioanalytical and DMPK leadership, including heads of bioanalysis/PK/DMPK, CRO scientific and operational directors, and laboratory leads in pharma and CROs
- Hands‑on bioanalytical innovators, including bioanalytical scientists, assay development and method transfer teams, laboratory automation leaders, and project managers overseeing bioanalytical timelines
Certificate of attendance
If you attend the live TechTalk, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand TechTalk, you can request a certificate of attendance by emailing editor@selectscience.net.
TechTalk details
- Cost: Free to attend
- Location: Online
- Duration: 20 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available
Automated approaches to improving immunoassays - SelectScience and Gyros Protein Technologies Podcast
At the Bioprocessing Summit in Boston, SelectScience® spoke with Todd Glynn from Gyros Protein Technologies for this special Podcast.
We spoke about the Gyrolab® immunoassay kits and solutions for cell and gene therapy viral vector titer and impurity analysis, and how they benefit their customers.
Anti-AAV antibody testing emerges as key to gene therapy
Advance gene therapy precision by reliably testing pre-existing AAV immunogenicity
How immunoassay innovation has expanded the biotherapeutic development toolbox
Experts share how commitment to bioanalytical innovation and quality has enabled success in biotherapeutic development
Automated approaches to improving immunoassays
Find out how the immunoassay kits from Gyros Protein Technologies can support your cell and gene therapy viral vector titer and impurity analyses
Gene therapy: Reliable capsid titer quantification for AAV-based therapeutics
Guest editorial: Technology to meet the challenge of efficiency in the regulated AAV vector space
New ultra-sensitive, automated immunoassays to streamline biopharma clinical assay development
EMD Serono senior scientist Carina Carter shares her experience with some of the latest immunoassay technology optimizing pharmacokinetics and immunogenicity assay development
